Given the side effects and potential addiction issues with opioid drugs, pain-drug specialist Purdue Pharma L.P. is exploring options for other mechanisms of actions. Last week the company announced a deal with Anabios Corp. to accelerate Purdue's Nav1.7 sodium ion channel preclinical drug candidates.